MB-105
CD5+ relapsed or refractory T-cell lymphomas (TCL)
Phase 2Active
Key Facts
Indication
CD5+ relapsed or refractory T-cell lymphomas (TCL)
Phase
Phase 2
Status
Active
Company
About March Biosciences
March Biosciences is a private, clinical-stage biotech founded in 2020 and headquartered in Houston, Texas. The company is developing a CAR-T cell therapy platform with an initial focus on CD5 as a target for treating relapsed/refractory T-cell malignancies, an area of high unmet need. It has advanced its lead candidate, MB-105, into a Phase 2 clinical trial, building on foundational research from Baylor College of Medicine. The company emphasizes a streamlined manufacturing process and a team with deep cell therapy expertise.
View full company profile